ReviewJournal of controlled release : official journal of the Controlled Release Society2008
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 256 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
256 citing papers in PubMed, 1,246 citations in OpenAlex.
- Oligosaccharide nanomedicine of alginate sodium improves therapeutic results of posterior lumbar interbody fusion with cages for degenerative lumbar disease in osteoporosis patients by downregulating serum miR-155.International journal of nanomedicine · 2017Trial
- Catheter-Deliverable Floating Hydrogels for Sustained Intravesical Drug Release.Gels (Basel, Switzerland) · 2026Article
- Polymeric Micelle Systems for Oral Drug Delivery of Small Molecule Therapeutics.Pharmaceutics · 2026Review
- Self-Assembly and Gelation Behavior of Methacrylated PEO-PPO-PEO Triblock Copolymer Pluronic F127.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- Metformin potentiates DSF/Cu-loaded pluronic nanoparticles to improve therapeutic efficacy in triple-negative breast cancer.BMC biotechnology · 2026Article
- Drug Combination in Polymeric Nanocarriers for Chemotherapy of Cancer: Preclinical Outcomes in the Last Ten Years.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.Pharmaceutics · 2026Review
- Development of a gene-activated matrix for enhanced AAV gene deliveryFrontiers in bioengineering and biotechnology · 2026Article
- Functional reprogramming of melittin by PluronicFrontiers in oncology · 2026Article
- Stimuli-Responsive Cell-Mimetic Vesicles for Advanced Pharmaceutical Systems.International journal of nanomedicine · 2026Review
- Tuning Pluronic Hydrogel Properties via Ionic Strength and Hyaluronic Acid for Optimized Rheology and Drug Delivery Performances.ACS omega · 2025Article
- Copper death combination therapy: the innovative frontier and challenges in prostate cancer treatment.Cancer biology & therapy · 2025Review
- Optimizing Pluronic-PEI Nanocarriers for RNAi Delivery in Oral Cancer: From Polymer Synthesis to Functional Screening.Biomacromolecules · 2025Article
- Advances in constructing biocompatible nanocarriers.Drug delivery and translational research · 2025Review
- Evaluation of Permeation Enhancers for Vaginal Delivery of Buserelin Acetate Using a Validated Chromatographic Method and Ex Vivo Porcine Model.Pharmaceutics · 2025Article
- Development and evaluation of new nanoformulated thiolactone derivatives for enhanced disruption of pseudomonal biofilms.RSC advances · 2025Article
- Poloxamer-based drug delivery systems: Frontiers for treatment of solid tumors.Materials today. Bio · 2025Review
- Article
- Investigating Extracellular Vesicles in Viscous Formulations: Interplay of Nanoparticle Tracking and Nanorheology via Interferometric Light Microscopy.Small science · 2025Article
- Molecular Interactions of the Antimicrobial Peptide Tritrpticin with Mixed Nanoaggregates: A Fluorescence Spectroscopy Study.Protein and peptide letters · 2025Article
196 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Polymer nanomaterials have sparked a considerable interest as vehicles used for diagnostic and therapeutic agents; research in nanomedicine has not only become a frontier movement but is also a revolutionizing drug delivery field. A common approach for building a drug delivery system is to incorporate the drug within the nanocarrier that results in increased solubility, metabolic stability, and improved circulation time. With this foundation, nanoparticles with stealth properties that can circumvent RES and other clearance and defense mechanisms are the most promising. However, recent developments indicate that select polymer nanomaterials can implement more than only inert carrier functions by being biological response modifiers. One representative of such materials is Pluronic block copolymers that cause various functional alterations in cells. The key attribute for the biological activity of Pluronics is their ability to incorporate into membranes followed by subsequent translocation into the cells and affecting various cellular functions, such as mitochondrial respiration, ATP synthesis, activity of drug efflux transporters, apoptotic signal transduction, and gene expression. As a result, Pluronics cause drastic sensitization of MDR tumors to various anticancer agents, enhance drug transport across the blood brain and intestinal barriers, and causes transcriptional activation of gene expression both in vitro and in vivo. Collectively, these studies suggest that Pluronics have a broad spectrum of biological response modifying activities which make it one of the most potent drug targeting systems available, resulting in a remarkable impact on the emergent field of nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.